Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug Screen Tugs at Common Thread for Repeat Disorders.

Kaalak Reddy1, John Douglas Cleary1, J Andrew Berglund2

  • 1RNA Institute, State University of New York at Albany, Albany, NY, USA.

Trends in Pharmacological Sciences
|January 14, 2020
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A simple, sensitive microsample LC-MS assay for quercetin and isorhamnetin in mouse and human plasma: application to EMIQ treatment in myotonic dystrophy type 1.

Bioanalysis·2026
Same author

Modified Polycyclic Compounds Rescue Mis-splicing in Myotonic Dystrophy Type 1 Disease Models.

ACS chemical biology·2026
Same author

Identification of enzymatically modified isoquercitrin as a therapeutic lead for myotonic dystrophy type 1.

NAR molecular medicine·2026
Same author

Inosine misincorporation into mRNA triggers the integrated stress response and activates an innate immune gene expression signature.

bioRxiv : the preprint server for biology·2026
Same author

Changes in RNA splicing as a surrogate endpoint for myotonic dystrophy Type 1 (DM1) clinical trials.

Journal of neuromuscular diseases·2025
Same author

Counterions influence the isothermal self-assembly of DNA nanostructures.

Science advances·2025

Repeat-associated non-ATG (RAN) translation drives disease in microsatellite expansion disorders. Researchers identified potential RAN translation inhibitors, offering a new therapeutic strategy for these conditions.

Area of Science:

  • Genetics
  • Neuroscience
  • Molecular Biology

Background:

  • Repeat-associated non-ATG (RAN) translation is a key pathogenic mechanism in microsatellite expansion disorders.
  • Fragile X tremor ataxia syndrome (FXTAS) is one such disorder where RAN translation is implicated.

Purpose of the Study:

  • To identify small-molecule inhibitors of RAN translation.
  • To establish a therapeutic strategy for microsatellite expansion disorders.

Main Methods:

  • High-throughput small-molecule screening was employed.
  • Screening was focused on identifying inhibitors relevant to fragile X tremor ataxia syndrome.

Main Results:

  • Several candidate RAN translation inhibitors were identified.
Keywords:
RAN translationRNA bindingmultiple targetstherapeutic compound screen

Related Experiment Videos

  • The study provides a validated screening approach.

    • Conclusions:

    • The identified compounds represent potential therapeutic leads for FXTAS.
    • This work paves the way for developing RAN translation inhibitors for various microsatellite expansion disorders.